A prospective cohort study on stereotactic radiotherapy in the management of dural recurrence of olfactory neuroblastoma.

Autor: Goodman CD; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada., DeMonte F; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Nguyen TP; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Garden AS; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Wang CH; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Wang XA; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Diao K; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Lee A; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Reddy J; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Moreno A; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Spiotto M; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Fuller CD; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Rosenthal D; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Ferrarotto R; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Raza SM; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Su SY; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Warner A; Department of Radiation Oncology, London Health Sciences Centre, London, Ontario, Canada., Hanna E; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA., Phan J; Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Jazyk: angličtina
Zdroj: Head & neck [Head Neck] 2024 Jul 29. Date of Electronic Publication: 2024 Jul 29.
DOI: 10.1002/hed.27887
Abstrakt: Background: Treatment for dural recurrence of olfactory neuroblastoma (ONB) is not standardized. We assess the outcomes of stereotactic body radiotherapy (SBRT) in this population.
Methods: ONB patients with dural recurrences treated between 2013 and 2022 on a prospective registry were included. Tumor control, survival, and patient-reported quality of life were analyzed.
Results: Fourteen patients with 32 dural lesions were evaluated. Time to dural recurrence was 58.3 months. Thirty lesions (94%) were treated with SBRT to a median dose of 27 Gy in three fractions. Two patients (3 of 32 lesions; 9%) developed in-field radiographic progression, five patients (38%) experienced progression in non-contiguous dura. Two-year local control was 85% (95% CI: 51-96%). There were no >grade 3 acute toxicities and 1 case of late grade 3 brain radionecrosis.
Conclusion: In this largest study of SBRT reirradiation for ONB dural recurrence to date, high local control rates with minimal toxicity were attainable.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: